Collaborations & Alliances

Lipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite

Supports late-stage development and scalable manufacturing for LP-310

Author Image

By: Charlie Sternberg

Associate Editor

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, has re-signed its manufacturing collaboration agreement with Cook MyoSite Inc. to support Chemistry, Manufacturing and Control (CMC) documentation supporting its clinical products LP-10 and LP-310. In April, Lipella shared positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a lipo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters